Drug Trial News

RSS

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

6 Jun 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

A new clinical trial studying the effectiveness of a combination of immunotherapy treatments could be more effective for patients with ovarian cancer who are resistant to traditional interventions.

6 Jun 2022

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.

6 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

$New combination of drugs increases survival time for some patients with refractory lung cancer$

New combination of drugs increases survival time for some patients with refractory lung cancer

A combination of the drugs ramucirumab and pembrolizumab reduced risk of death by 31% compared with the standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.

3 Jun 2022

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.

3 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Researchers receive $1.1 million to study the safety, efficacy of drug combination for chronic pancreatitis

Researchers from Indiana University School of Medicine are studying the safety and efficacy of a drug combination for patients with chronic pancreatitis (CP).

2 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

In cardiovascular outcome trials among adults with type 2 diabetes (T2D), sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have shown therapeutic promise, including reduced risk of hospitalization for heart failure compared to placebo.

1 Jun 2022

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology.

31 May 2022

Mucosal COVID vaccine candidate powerfully protective in macaques

A recent research paper posted to the bioRxiv* preprint server illustrated the protective efficacy of the intranasal pediatric parainfluenza virus-vectored coronavirus disease 2019 (COVID-19) vaccine prospect, B/HPIV3/S-6P, in macaques.

26 May 2022

Study compares different types of moisturizers for children with eczema

The Best Emollients for Eczema trial has found that no one type of moisturizer is better than another. This study, the first in the world to directly compare different types of moisturizers, highlights the importance of patient education and choice when deciding which moisturizers to use for children with eczema.

26 May 2022

STIs could be prevented with a dose of doxycycline after unprotected sex

A significant proportion of bacterial sexually transmitted infections (STIs) - gonorrhea, chlamydia or syphilis - were prevented with a dose of doxycycline after unprotected sex, according to preliminary results of a clinical trial that closed early because it was very effective for men who have sex with men and transgender women who are living with HIV or are taking HIV pre-exposure prophylaxis (PrEP).

25 May 2022

Widely used Type 2 diabetes drug does not prevent breast cancer spread, landmark trial finds

A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.

24 May 2022

Improving Patient Recruitment for Clinical Trial Research

In this interview, we speak to Matt Walz, CEO of Trialbee, about the importance of improving patient recruitment and retention within clinical trials.

From Trialbee 23 May 2022

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during the chronic maintenance period.

20 May 2022

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research published at the ATS 2022 international conference.

18 May 2022

Previous
1
...
37
38
39
40
41
42
43
...
1148
Next

Drug Trial News

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

New combination of drugs increases survival time for some patients with refractory lung cancer

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Researchers receive $1.1 million to study the safety, efficacy of drug combination for chronic pancreatitis

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

Mucosal COVID vaccine candidate powerfully protective in macaques

Study compares different types of moisturizers for children with eczema

STIs could be prevented with a dose of doxycycline after unprotected sex

Widely used Type 2 diabetes drug does not prevent breast cancer spread, landmark trial finds

Improving Patient Recruitment for Clinical Trial Research

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News